Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma
Status:
Recruiting
Trial end date:
2026-03-16
Target enrollment:
Participant gender:
Summary
This is a Phase 1b study consisting of 2 parts: a dose escalation (Part 1) of CC-220 or
CC-99282 added to the standard R-CHOP-21 regimen for first-line treatment of a-BCL. The dose
escalation (Part 1) will consist of 2 parallel arms in combination with Rituximab,
Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP-21); CC-220 and R-CHOP-21
or CC-99282 and R-CHOP-21. Part 1 will be followed by a randomized dose expansion (Part 2)
with CC-220 and/or CC-99282 at the Recommended Phase 2 Dose (RP2D) in combination with
R-CHOP-21.